Filing Flows › TherapeuticsMD (TXMD) › Q1 2026
TherapeuticsMD (TXMD) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
TherapeuticsMD (TXMD) reported revenue of $724K for the first quarter 2026 (Q1 2026), +84% from a year earlier and -19% from the quarter before. Operating margin was -99.9%, net earnings $95K (13.1% of revenue).
TherapeuticsMD, Q1 2026: revenue $724K (+84% year over year), operating margin -99.9%, net earnings $95K, operating cash flow $944K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $724K | -19% | +84% |
| Operating profit | −$723K | — | — |
| Net earnings | $95K | — | — |
| Operating cash flow | $944K | +152% | +35% |
What changed
Revenue was $724K in Q1 2026, up 84% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $723K, an operating margin of -99.9%. Total costs fell 14% while revenue rose 84%. Net earnings were $95K. The effective tax rate was 7.8%. Non-operating items added $826K, 802% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $944K (up 35% year over year), 994% of net earnings. Non-cash charges added back $94K of depreciation and amortization and $2K of share-based compensation. Working capital and other items added $753K. Capital expenditures of $12.1M exceeded it, leaving free cash flow of −$11.2M.
Questions
What was TherapeuticsMD's revenue in the first quarter 2026?
TherapeuticsMD (TXMD) reported revenue of $724K for the first quarter 2026 (Q1 2026), +84% from a year earlier and -19% from the quarter before.
Was TherapeuticsMD profitable in the first quarter 2026?
Operating loss was $723K (-99.9% of revenue) and net earnings $95K.
Source: TherapeuticsMD 10-Q on SEC EDGAR.